- 2003.- №167 P.24-33.inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease/SD Aaron, G.B. Angel, M. Lunau//Am. J. Respir .Crit. Care Med. 2001. - Vol. 163, №2.-P. 349 - 355.
Імунна система та її дефекти: керівництво для лікарів/за ред. Фрейдліна І.С .// изд.-во СПб.Б.і., 1998. - 168 с.:Does COPD have an autoimmune component?/A. Agusti., W. MacNee., K. Donaldson//Thorax. 2003. - №38.- P. 832 - 834.term repeatability in inducted sputum cells and inflammatory markers in stable, moderatelly severe COPD/KM Been, J. Beier, O. Kornmann//Chest. 2005. - Vol. 113, №4.- P. 754 - 757 .. Tobacco smoke and respiratory disease./J. Behr, D. Nowak//Eur. Respir. Mon. 2002. -№21.- P. 161-179.and the pathogenesis of COPD.// Chest. 2002. -№121.-P. 151-155.concepts in chronic obstructive pulmonary disease//Annu. Rev. Med. 2003. - №54.- P. 113 - 129.condensate as a method of noninvasive assessment of inflammation mediators from the lower airways ERS/G.Becher, K. Winsel, E. Beck//Annual Congress.- Stockolm.- 2002. P. 163 - 169. oxide and lung disease/PJ. Barnes, M.G. Beivisi//Thorax.- 1993. -Vol. 48. -P. 1034-1043
Чучалин, А.Г. Хронічна обструктивна хвороба легень. Монографія. М.-Атмосфера.- 2008, - 541 с.
Шмельов, Є.І. Хронічна обструктивна хвороба легень. Монографія. М.: Атмосфера.- 2003. - 112 с.of Interleukin - 8 in the pathogenesis and Treatment of COPD/DS Antonino, C. Armando, F.D. Claudio//Chest.- 2004.- №126; P. 676-678.exacerbations: definitions and classifications/Burge S. Wedzicha JA// Eur. Respir. J. 2003. - Vol. 21, №41.- P. 46- 53.and effects of fine and ultrafme particles in respiratory tract/K. Donaldson, C. Lang Tran, W. MacNee//Eur. Respir. Mon.- 2002. -№21.-P.77 92.cytokine profiling and enrichment analysis reveal the involvement of immunological and inflammatory pathways in stable patients with chronic obstructive pulmonary disease/ lt; # 24 src= doc_zip1.jpg / gt; Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. lt; http: //ncbi.nlm.nih.gov/pubmed/25004813gt;/Roncarolo MG, Gregori S, Bacchetta R, Battaglia M//Curr Top Microbiol Immunol. 2 014; 380: 39-68. doi: 10.1007
Antioxidants, inflammation and cardiovascular disease lt; http: //ncbi.nlm.nih.gov/pubmed/24976919gt;/Mangge H, Becker K, Fuchs D, Gostner JM//World J Cardiol. 2 014 Jun 26; 6 (6): 462-77. doi: 10.4330Review.responsiveness of CD8 (+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients lt; http: //ncbi.nlm.nih.gov/pubmed/24883189gt;/Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM//JImmunother Cancer. 2 014 May 13; 2: 10. doi: 10.1186of potential biomarkers of disease progression in bovine tuberculosis/ lt; http: //ncbi.nlm.nih.gov/pubmed/24856732gt; Blanco FC, Bigi F, Soria MA//Vet Immunol Immunopathol. 2 014 Aug 15; 160 (3-4): 177-83. doi: 10.1016 /ni.2866. Epub +2014 May 6.reduces CD40L expression and modifies cytokine production in the CD4 cells of pollen allergy patients lt; http: //ncbi.nlm.nih.gov/pubmed/24834772gt;/Urra JM, Carrasco P, Feo-Brito F, De La Roca F, Guerra F, Cabrera CM//J Investig Allergol Clin Immunol. 2 014; 24 (2): 98-105.timing of HAART is less more? CD4 +/CD8 + ratio and CD4 + percentage as surrogate markersfor more complex immunological features. lt; http: //ncbi.nlm.nih.gov/pubmed/24531173gt;/Fogli M, Iaria M, Foc? E, Giagulli C, Caccuri F, Maggi F, Torti C, Caruso A, Fiorentini S .// New Microbiol. 2 014 Jan; 37 (1): 75-80. Epub +2014 Jan 15.of immunotoxicity for environmental and public health research lt; http: //ncbi.nlm.nih.gov/pubmed/21655126gt;/Duramad P, Holland NT .// Int J Environ Res Public Health. +2011 May; 8 (5): 1388-401. doi: 10.3390/ijerph8051388. Epub +2011 May 6. Review.and chronic obstructive pulmonary disease lt; http: //ncbi.nlm.nih.gov/pubmed/19638929gt;/Guerra S .// Curr Opin Allergy Clin Immunol. +2009 Oct; 9 (5): 409-16. doi: 10.1097/ACI.0b013e3283300baf. Review.taught by lung dendritic cells lt; http: //ncbi.nlm.nih.gov/pubmed/19137454gt;/von Garnier C, Nicod LP .// Swiss Med Wkly. 2 009 Apr 4; 139 (13-14): 186-92. doi: smw - 12151. Review.levels of CA - 50, CA - 19.9, CA - 125, CA - 15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung. lt; http: //ncbi.nlm.nih.gov/pubmed/3178158gt;/Marechal F, Berthiot G, Deltour G .// Anticancer Res. Одна тисячі дев'ятсот вісімдесят вісім Jul-Aug; 8 (4): 677-80.of thrombophilia in pulmonary fibrosis complicated by pulmonary hypertension/Arkhipova DV lt;http://ncbi.nlm.nih.gov/pubmed?term=Arkhipova%20DV%5BAuthor%5Damp;cauthor=trueamp;cauthor_uid=15108458gt;, Privalova EV lt;http://ncbi.nlm.nih.gov/pubmed?term=Privalova%20EV%5BAuthor%5Damp;cauthor=trueamp;cauthor_uid=15108458gt;, Kozlovskaia LV lt;http...
